Tag: FDA

FDA Approvals (July 2024 – January 2025): Advancements in Cardiorenal and Cardiometabolic Health 

Get the latest FDA-approved drugs and devices for cardiometabolic and cardiorenal conditions and risk factors. Explore now!

The Cardiometabolic Event of the Year: What to Expect at the 19th Annual Cardiometabolic Health Congress (CMHC) 

Discover what you can expect at the 19th Annual Cardiometabolic Health Congress (CMHC) – the biggest conference in cardiorenal metabolic health!

2024’s Mid-Year Review: FDA-Approved Cardiorenal Metabolic Drugs and Devices 

The first half of 2024 ushered in a wave of transformative FDA approvals in cardiorenal metabolic health. Get up to date now!

2022 FDA-Approved Cardiometabolic Drugs and Devices

Although the U.S. Food and Drug Administration (FDA) approved a record-low number of drugs and devices from January through September 2022, many of those were in the realm of cardiorenal metabolic health. January 2022 Daridorexant. In the first major move of 2022, the FDA approved daridorexant for the treatment of adults with insomnia on Jan. […]